• Home
  • Forum
  • Demo Day
  • Home
  • Demo Day
profile

Wyss Institute

Wyss Institute

Founded 2009
Boston, Massachusetts, United States
Stage: No stage info

Get updates & announcements

Get updates & announcements

About
Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Contact Details

email

Info@wyss.harvard.edu

website

https://wyss.harvard.edu

twitter
linkedin
telegram
blog

https://wyss.harvard.edu/news/

bluesky
crunchbase

Community Affiliations

Members (1)

Anastasia Ershova

Anastasia Ershova

Staff Scientist

goto

Members (1)

Anastasia Ershova

Anastasia Ershova

Staff Scientist

goto

Focus Areas

Projects

Add projects associated with this team.

Projects (0)

search

No Projects found.

Wyss Institute News (20)

Wyss Institute Study Identifies SRSF1 Gene as Anti-Aging Target, Extends Mouse Lifespan…

A Wyss/Harvard team led by George Church published in Nature Aging a screen identifying the SRSF1 RNA-processing gene as reversing multiple aging hallmarks while preserving cell identity.

FundingSourcesnews-medical.nettechnologynetworks.comnature.com12d ago
3 Views

FDA Recognizes Organ-on-Chip as Viable Drug Testing Alternative

The FDA updated regulations to accept non-animal methods—including the Wyss Institute's organ-on-chip technology—as scientifically valid nonclinical testing.

OtherSourceswjla.comtechnews.tw21d ago
209 Views

Wyss researchers publish self-assembled cancer vaccine that cleared tumors in 70% of…

The in situ approach uses two-component nanostructures to trigger immunogenic cell death without patient-specific antigen manufacturing, offering a potentially scalable alternative to personalized cancer vaccines.

AnnouncementSourcesadvanced.onlinelibrary.wiley.commgriblog.org27d ago
129 Views
All network updates